
Sign up to save your podcasts
Or


Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.
By Venrock, a venture capital firm4.8
6262 ratings
Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.

1,296 Listeners

2,672 Listeners

2,461 Listeners

1,105 Listeners

341 Listeners

337 Listeners

394 Listeners

5,610 Listeners

10,254 Listeners

34 Listeners

551 Listeners

21 Listeners

300 Listeners

475 Listeners

1,480 Listeners